Description

Guerbet S.A. is a medical technology company focused on the innovation and commercialization of contrast media products, specialized delivery systems, medical devices, and related solutions. Its comprehensive portfolio includes a range of contrast agents such as Optiray and Xenetix, which are non-ionic iodinated agents; Telebrix Gastro, a meglumine ioxitalamate solution; Conray, an iothalamate meglumine injection; and Micropaque/Microtrast for diagnostic imaging. For MRI applications, it offers Dotarem (gadoteric acid-gadoterate meglumine) and Artirem (gadoteric acid). Beyond contrast agents, Guerbet supplies essential equipment like prefilled syringes, injectors, and various accessories and consumables tailored for MRI, CT, and Cath Lab procedures. The company also pioneers digital health solutions, featuring Contrast&Care for managing injections, Dose&Care for X-ray dose management, and icobrain, a cloud-based artificial intelligence tool that quantifies disease-specific brain structures from MR and CT images for acute and chronic neurological conditions, complemented by OptiProtect services. In the field of interventional radiology, its products include Lipiodol (ethyl esters of iodinated fatty acids derived from poppyseed oil); Vectorio, a mixing and injection system for conventional trans-arterial chemoembolization; Patent Blue V, a blue dye; Axessio, a peripheral micro guidewire; and the microcatheters SeQure and DraKon. Furthermore, Guerbet provides Hydra Vision, a digital imaging system utilized for urological, gastroenterological, and gynecological treatments, planning, and diagnostics, along with associated urology accessories and consumables. Founded in 1926, Guerbet S.A. is headquartered in Villepinte, France.